Preparation of amifostine polylactide-co-glycolide microspheres and its irradiation protective to mouse through oral administration

References

• Anné PR, Curran WJ Jr. (2002). A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer. Semin Radiat Oncol, 12:18–19.
   PubMed Web of Science ®Google Scholar
• Tarnuzzer RW, Colon J, Patil S, Seal S. (2005). Vacancy engineered ceria nanostructures for protection from radiation-induced cellular damage. Nano Lett, 5:2573–2577.
   PubMed Web of Science ®Google Scholar
• Mabro M, Faivre S, Raymond E. (1999). A risk-benefit assessment of amifostine in cytoprotection. Drug Saf, 21:367–387.
   PubMed Web of Science ®Google Scholar
• Sriswasdi C, Jootar S, Giles FJ. (2000). Amifostine and hematologic effects. J Med Assoc Thai, 83:374–382.
   PubMedGoogle Scholar
• Lindegaard JC, Grau C. (2000). Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol, 57:113–118.
   PubMed Web of Science ®Google Scholar
• Barutca S, Meydan N, Akar H, Yavasoglu I, Kadikoylu G, Bolaman Z. (2004). Efficacy and tolerability of amifostine in elderly cancer patients. Current Therapeutic Res, 65:113–124.
   PubMed Web of Science ®Google Scholar
• Lialiaris TS, Kotsiou E, Pouliliou S, Kareli D, Makrinou H, Kouskoukis A et al. (2009). Cytoprotective activity of amifostine on cultured human lymphocytes exposed to irinotecan. Food Chem Toxicol, 47:2445–2449.
   PubMed Web of Science ®Google Scholar
• Grdina DJ, Murley JS, Kataoka Y, Baker KL, Kunnavakkam R, Coleman MC et al. (2009). Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response. Int J Radiat Oncol Biol Phys, 73:886–896.
   PubMed Web of Science ®Google Scholar
• McDonald S, Meyerowitz C, Smudzin T, Rubin P. (1994). Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys, 29:747–754.
   PubMed Web of Science ®Google Scholar
• Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. (2002). Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys, 52:739–747.
   PubMed Web of Science ®Google Scholar
• Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. (2004). Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol, 70:261–264.
   PubMed Web of Science ®Google Scholar
• Schuchter LM. (1996). Guidelines for the administration of amifostine. Semin Oncol, 23:40–43.
   PubMed Web of Science ®Google Scholar
• Capizzi RL. (1999). Clinical status and optimal use of amifostine. Oncology (Williston Park, NY), 13:47–59; discussion 63, 67.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Pendergrass JA Jr, Kumar KS, Landauer MR, Seed TM. (2002). Radioprotection, pharmacokinetic and behavioural studies in mouse implanted with biodegradable drug (amifostine) pellets. Int J Radiat Biol, 78:535–543.
   PubMed Web of Science ®Google Scholar
• Bonner HS, Shaw LM. (2002). New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J Clin Pharmacol, 42:166–174.
   PubMed Web of Science ®Google Scholar
• Cassatt DR, Fazenbaker CA, Bachy CM, Hanson MS. (2002). Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy. Semin Radiat Oncol, 12:97–102.
   PubMed Web of Science ®Google Scholar
• Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z et al. (2002). Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol, 12:46–49.
   PubMed Web of Science ®Google Scholar
• Schuchter LM, Hensley ML, Meropol NJ, Winer EP; American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. (2002). 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol, 20:2895–2903.
   PubMed Web of Science ®Google Scholar
• Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM. (2003). Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model. Int J Radiat Oncol Biol Phys, 57:794–802.
   PubMed Web of Science ®Google Scholar
• Godette KD, Thomas CR Jr. (2001). Clarification on the potential of subcutaneous ethyol as a radioprotective agent. J Clin Oncol, 19:1582–1583.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Romanidis K, Froudarakis M, Kyrgias G, Koukourakis GV, Retalis G et al. (2002). Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer, 87:385–392.
   PubMed Web of Science ®Google Scholar
• de Castro G Jr, Federico MH. (2006). Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients. Curr Opin Oncol, 18:266–270.
   PubMed Web of Science ®Google Scholar
• Mandal TK, Bostanian LA, Graves RA, Chapman SR. (2002). Poly(D,L-lactide-co-glycolide) encapsulated poly(vinyl alcohol) hydrogel as a drug delivery system. Pharm Res, 19:1713–1719.
   PubMed Web of Science ®Google Scholar
• Mandal TK, Bostanian LA, Graves RA, Chapman SR, Womack I. (2002). Development of biodegradable microcapsules as carrier for oral controlled delivery of amifostine. Drug Dev Ind Pharm, 28:339–344.
   PubMed Web of Science ®Google Scholar
• Pamujula S, Graves RA, Kishore V, Mandal TK. (2004). Preparation and in vitro characterization of amifostine biodegradable microcapsules. Eur J Pharm Biopharm, 57:213–218.
   PubMed Web of Science ®Google Scholar
• Pamujula S, Graves RA, Moiseyev R, Bostanian LA, Kishore V, Mandal TK. (2008). Preparation of polylactide-co-glycolide and chitosan hybrid microcapsules of amifostine using coaxial ultrasonic atomizer with solvent evaporation. J Pharm Pharmacol, 60:283–289.
   PubMed Web of Science ®Google Scholar
• Cun D, Foged C, Yang M, Frøkjaer S, Nielsen HM. (2010). Preparation and characterization of poly(DL-lactide-co-glycolide) nanoparticles for siRNA delivery. Int J Pharm, 390:70–75.
   PubMed Web of Science ®Google Scholar
• Dillioglugil MO, Kir HM, Demir C, Ilbay G, Sahin D, Dillioglugil O et al. (2010). Effect of pentylenetetrazole and sound stimulation induced single and repeated convulsive seizures on the MDA, GSH and NO levels, and SOD activities in rat liver and kidney tissues. Brain Res Bull, 83:356–359.
   PubMed Web of Science ®Google Scholar